Overall market sentiment has been high on Aurinia Pharmaceuticals Inc (AUPH) stock lately. AUPH receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Aurinia Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AUPH!
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With AUPH Stock Today?
Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $18.07 as of 10:37 AM on Wednesday, Sep 8, a drop of -$0.08, or -0.44% from the previous closing price of $18.15. The stock has traded between $18.00 and $18.68 so far today. Volume today is low. So far 1,024,733 shares have traded compared to average volume of 4,650,913 shares.
More About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.
Click Here to get the full Stock Report for Aurinia Pharmaceuticals Inc stock.